Concord Biotech's shares surged by 6% following the U.S. Food and Drug Administration's approval of its Tofacitinib Tablets. This regulatory nod, announced by the company, is a significant step in its strategy to strengthen its presence in the U.S. market by expanding its product portfolio.
The approval covers Tofacitinib Tablets for the treatment of various conditions including moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderately to severely active ulcerative colitis, and active polyarticular course juvenile idiopathic arthritis. Concord Biotech emphasized that this aligns with its growth strategy and enhances its ability to compete in the U.S. and international markets.
According to market estimates cited by Concord Biotech, the U.S. market opportunity for Tofacitinib Tablets at 5 mg and 10 mg strengths is approximately $500 million. This approval pertains specifically to the company's ANDA for these dosage strengths, supporting its long-term growth plans.
The company's recent financial performance showed a 36.8% year-on-year decline in fourth-quarter net profit to Rs 88.8 crore, with revenue from operations falling 24.1% to Rs 326.1 crore. EBITDA for the quarter declined 37.8% year-on-year to Rs 118.5 crore, with the EBITDA margin contracting to 36.4% from 44.3% in the previous year.
Concord Biotech's share price has decreased by 36% over the past year, highlighting the challenges it faces amidst market fluctuations and competitive pressures.
Background
This approval marks a critical development for Concord Biotech, as it seeks to leverage the U.S. market's potential and bolster its financial performance.
Investors and market analysts will be closely watching the company's next moves and its impact on the stock performance.
